Clinical Trials Browser

Phase 1/2 × INDUSTRY × HMPL-013 × Clear all

Advanced Solid Tumors

NCT05405595 2026-01-07

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

186 enrolled

Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT05565417 2025-10-16

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Phase 1/2 Active not recruiting

67 enrolled

BreastGastrointestinalHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

52 enrolled 23 charts

BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03903705 2025-04-06

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Phase 1/2 Completed

348 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT01975077 2020-02-17

A Phase Ib Study of Fruquintinib in 3rd Line mCRC

Phase 1/2 Completed

62 enrolled

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

A Phase Ib Study of Fruquintinib in 3rd Line mCRC